Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan therapeutic dose Treatment A
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan supra-therapeutic dose Treatment B
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [moxifloxacin] on Day 2 Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active control [Moxifloxacin] on Day 15 Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment C
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Balovaptan Treatment D
Description: Days 1-14: Matching placebo for balovaptan for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment A
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.